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Abstract
Alpha-synuclein (a-Syn) accumulation/aggregation and mitochondrial dysfunction play prominent roles in the pathology of
Parkinson’s disease. We have previously shown that postmortem human dopaminergic neurons from PD brains accumulate
high levels of mitochondrial DNA (mtDNA) deletions. We now addressed the question, whether alterations in a component
of the mitochondrial import machinery -TOM40- might contribute to the mitochondrial dysfunction and damage in PD. For
this purpose, we studied levels of TOM40, mtDNA deletions, oxidative damage, energy production, and complexes of the
respiratory chain in brain homogenates as well as in single neurons, using laser-capture-microdissection in transgenic mice
overexpressing human wildtype a-Syn. Additionally, we used lentivirus-mediated stereotactic delivery of a component of
this import machinery into mouse brain as a novel therapeutic strategy. We report here that TOM40 is significantly reduced
in the brain of PD patients and in a-Syn transgenic mice. TOM40 deficits were associated with increased mtDNA deletions
and oxidative DNA damage, and with decreased energy production and altered levels of complex I proteins in a-Syn
transgenic mice. Lentiviral-mediated overexpression of Tom40 in a-Syn-transgenic mice brains ameliorated energy deficits
as well as oxidative burden. Our results suggest that alterations in the mitochondrial protein transport machinery might
contribute to mitochondrial impairment in a-Synucleinopathies.
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Introduction
Mitochondrial dysfunction is believed to play a pivotal role in
the pathogenesis of Parkinson’s disease (PD) [1,2]. Decreases in
activity and protein concentration of electron transport chain
(ETC) complex I are consistently found in brains and other tissues
of PD patients [3,4,5]. Moreover, strong associations have been
identified between genes causing familial PD syndromes and
mitochondrial function [1]. Previous reports, including work from
our group, showed significantly higher levels of somatic deletions
in mitochondrial DNA (mtDNA) in individual post mortem
dopaminergic neurons from PD and aged patients compared to
non-PD or younger controls [6,7].
Alpha-synuclein (a-Syn) is an abundant presynaptic molecule
[8] and a major component of Lewy bodies (LB) and Lewy
neurites, which are neuropathological hallmarks of PD in the
substantia nigra (SN) [9]. Its progressive intraneuronal aggregation
has been proposed to play a central role in idiopathic PD and
highlights its neurotoxic potential [10,11]. Mutations or multi-
plications in the gene encoding a-Syn cause autosomal dominant
familial Parkinson syndromes (PARK1 and PARK4) [12,13].
Overexpression of human wt-a-Syn in transgenic (tg) mice leads to
motor deficits, dopaminergic loss, and formation of inclusion
bodies, thereby mimicking certain aspects of a PD phenotype [14].
While it is yet not fully understood which are the mechanisms
involved in a-Syn-mediated neuronal injury, an increasing body of
evidence suggests that mitochondrial dysfunction plays an
important role in this process [2,15,16]. Alpha-Syn was recently
reported to localize to mitochondria [17,18,19]. Human a-Syn has
a cryptic mitochondrial targeting sequence at its N-terminal
domain that might facilitate its transport by the mitochondrial
protein import machinery [20]. The close association between a-
Syn and mitochondria is also reflected by the fact that a-Syn
knockout mice are resistant to mitochondrial damage caused by
complex I inhibitors, which usually lead to a PD-like phenotype in
mammals and rodents [21,22].
In the present study we investigated a-Syn-induced mitochon-
drial toxicity. We show that a-Syn causes mitochondrial dysfunc-
tion and DNA damage in vitro as well as in vivo. We present
evidence showing that oxidative stress and impaired mitochondrial
function are mechanisms contributing to this damage, mediated
mainly by a decrease in the mitochondrial outer membrane
transport protein, TOM40 (translocase of the outer mitochondrial
membrane). Overexpression of TOM40 in a-Syn transgenic mice
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e62277
successfully ameliorated the mitochondrial deficits, suggesting it
might represent a novel target for PD therapies.
Materials and Methods
Ethics Statement
Experiments involving human samples were approved by the
Institutional Review Boards of the University of Munich as well as
the German Brain Bank, BrainNet (Permit Number: GA44), in
Munich. All investigations involving human samples have been
conducted according to the principles expressed in the Declaration
of Helsinki. Written informed consent was obtained from all
participating subjects, where appropriate.
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the University of California San Diego (UCSD,
Permit Number: S02221). All surgery was performed under
anesthesia, and all efforts were made to minimize suffering.
Animals
For this study we used heterozygous transgenic mice (Line D)
expressing wild type human a-Synuclein under the regulatory
control of the platelet-derived growth factor-b (PDGFb) promoter
[14] (n = 15/group, 5 months-old; 8 females, 7 males). These mice
develop intra-neuronal accumulation of a-Syn aggregates through-
out the hippocampus and neocortex, similar to what is observed in
patients with PD and Lewy-Body disease [14].
Tissue Processing and Immunohistochemistry
Following NIH guidelines for the humane treatment of animals,
mice were sacrificed under anesthesia and brains were removed.
The right hemibrain was immersion-fixed in 4% paraformalde-
hyde in pH 7.4 phosphate-buffered saline and serially sectioned at
40 mm with a vibratome (Leica, Deerfield, Illinois, USA). The left
hemibrain was immediately snap frozen in liquid nitrogen and
kept at 280uC until further processing.
For laser capture-microdissection (LCM) of a-Syn-positive or
a-Syn-negative neurons, 10 mm thick cryosections including the
hippocampus and posterior cortex were cut on special
membrane slides (Leica Microsystems, Germany). Sections were
briefly fixed in ice-cold acetone and double-labeled with
fluorescently-conjugated primary antibodies for anti-NeuN
(1:200, Chemicon, Temecula, CA, USA) and anti-a-Syn
(1:100, Chemicon, Temecula, California, USA). Fluorescent
labeling of the anti-a-Syn-antibody was done with the Alexa
FluorH 488 (green) Monoclonal Antibody Labeling Kit while the
anti-NeuN-antibody was labeled with Alexa FluorH 594 (red;
both Molecular Probes, Eugene, OR, USA). Primary antibodies
were incubated for 1 hour at room temperature followed by
dehydration in alcohol and air drying for 15 minutes. LCM of
neurons with and without intensive a-Syn-immunostaining was
performed on a Leica LMD 6000 LCM (Leica, Wetzlar,
Germany). About 20 neurons per animal were picked from
posterior cortex adjacent to the hippocampus and collected in
one PCR tube. Samples were collected in triplicate.
Fixed brain sections were used for the immunostaining of
markers of oxidative DNA damage (8-Hydroxy-2’-deoxyguano-
sine, 8-OHdG, 1:200), TOM40 and TOM20 (both from Santa
Cruz Biotechnology, Santa Cruz, CA, at 1:250) and a-Syn-
accumulation (1:1,000, both Chemicon, Temecula, California,
USA). Primary antibodies were incubated overnight, followed by
detection with species-appropriate secondary antibodies (1:2000,
Vector Laboratories, Burlingame, Ca, USA) and developed with
3,39-Diaminobenzidine (DAB). Sections were transferred to
SuperFrost slides (Fisher Scientific, California, USA) and mounted
with anti-fading media (Vector Laboratories).
Detection and Quantification of mtDNA Deletions and
mtDNA Copy Number
For mtDNA analysis of brain homogenates, the posterior half of
frozen hemibrains was homogenized with 20 strokes of a Dounce
homogenizer in 200 ml of cold PBS. Total DNA was extracted
from half of this homogenate (DNeasy Blood & Tissue Kit,
Qiagen, Hilden, Germany), the other half was used for RNA
extraction. DNA concentration and purity was determined by
UV-spectrophotometry at 260/280 nm. For the analysis of single
cells after LCM, mtDNA was extracted with QIAmp DNA Micro
Kit (Qiagen) according to the manufacturer’s protocol and eluted
in 20 ml of ddH20.
Low-abundance mtDNA deletions were detected by a two-step
nested long-range PCR protocol (Expand Long Range
dNTPackH, Roche, Mannheim, Germany) to amplify a final
,10 kb fragment of the deletion-prone ‘‘major arc’’ of the
mitochondrial genome as we previously reported [6,23]. In brief,
first round PCR reactions were done on 10 ng of template DNA
under standard conditions and using 30 pmol each of forward
(mtDNA nt 4796-4817) and reverse (mtDNA nt 16020-16001)
primers. Amplifications were carried out using a GeneAmpH PCR
System 9600 (Applied Biosystems, Carlsbad, CA, USA) with the
following cycling conditions: 3 minutes at 93uC; 10 cycles of 93uC
for 30 sec, 58uC for 30 sec, 68uC for 12 min; 20 cycles of 93uC for
30 sec, 58uC for 30 sec, 68uC for 12 min +5 sec per additional
cycle; final extension of 11 min at 68uC. This reaction product was
then diluted 1:50 and 1 ml was used as template in a second round
of PCR amplification under similar conditions but with primers
mtDNA nt 5591–5610 and mtDNA nt 15221–15000. Amplified
products were separated through 0.8% agarose gels containing
ethidium bromide and visualized over UV light.
The levels of mtDNA deletion (percentage of total mtDNA
affected by deletions) were quantified by a real-time PCR assay,
which we previously established for human mtDNA [24,25], based
on the differential detection of DNA regions comprised in the
deletions and that serves as target sequences for amplification. We
designed three sets of primers and sequence specific probes (FAM/
MGB-labeled TaqManH probes, Applied Biosystems), which span
the mtDNA molecule with roughly the same distance between
them. Primers covered the ND1-gene nt3112-3136 (F) and
nt3210-3176 (R), and probes were nt3154-3169; COX3 gene,
nt8921-8945 (F) and nt8998-8974 (R) and cytochrome b (CytB)
gene, nt14614-14639 (F) and nt14718-14694 (R). Real-time PCR
reactions were performed with TaqManH Gene Expression Master
Mix (Applied Biosystems) and 50ng of template DNA extracted
from brain homogenates, or 2 ml of total DNA in the case of single
cell experiments. Amplification conditions were 2 min at 50uC,
10 min at 95uC then 40 cycles of 15 s at 95uC and 1 min at 60uC.
PCR reactions were performed on a StepOne Plus 96-well format
system (Applied Biosystems). Deletion levels (in % of total mtDNA)
were calculated using relative quantification according to the
formula (1–22DDCt)*100 as we previously reported in more detail
[24]. Relative mtDNA copy number was determined by compar-
ing the highest quantity of the three mtDNA genes to a nuclear
endogenous control gene (b-Actin, ACTB TaqManH assay,
Applied Biosystems).
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Tissue Extraction, Isolation of Mitochondria and
Quantification of ATP
Frozen anterior hemibrains were homogenized by sonication in
200 ml ice cold PBS and immediately snap frozen in liquid
nitrogen and stored at 280uC. 5 ml of this homogenate was used
for quantification of protein concentration by BCA protein assay
(Pierce, Rockford, IL, UA). Quantification of ATP levels was done
with a luciferase assay (CellTiter-GloH, Promega, Madison, WI,
USA) and normalized by protein. All experiments were performed
in triplicate.
Intact mitochondria were isolated from anterior hemibrains by
differential centrifugation (Mitosciences, Eugene, OR, USA). As
recommended, isolations were performed on ice and buffers were
supplemented with phosphatase and protease inhibitors (Roche).
Proteins were extracted from isolated mitochondria with RIPA
lysis buffer and centrifugation for 10 minutes at 10,000 RPM.
Western Blot Analysis
TOM40, TOM20 and respiratory chain subunit protein levels
were determined by immunoblot analysis from isolated mitochon-
dria. Briefly, 20 mg of total extracted mitochondrial protein were
resolved by electrophoresis in 12% Bis-Tris SDS-PAGE gels
(Invitrogen, Carlsbad, CA, USA) and transferred onto Immobilon
membranes. Primary antibodies against subunits of all five
respiratory chain complexes (MitoProfileH Total OXPHOS
rodent Antibody Cocktail, Mitosciences, Eugene, OR, USA) or
against TOM40 or TOM20 (both Santa Cruz Biotechnology)
were all incubated in a 1:1,000 dilution overnight at 4uC and
developed on a VersaDoc gel-imaging system (Bio-Rad, Hercules,
CA). Beta-actin levels, detected by anti-ACTB antibody (1:1,000,
Sigma), were used to normalize loading. The Quantity One
software package (Bio-Rad, Hercules, CA) was used for densi-
tometry analysis.
In vitro Analysis of TOM40 Levels and Oxidative Stress
Markers on a-Syn-Overexpression B103 System
B103 rat neuroblastoma cells were grown under standard
conditions in DMEM supplemented with 10% FBS and 1x
PenStrep (Life Technologies) and incubated at 37uC with 5%
CO2-supplemented air. Cells were infected with lentiviral vectors
encoding human wild-type a-Syn or A53T or A30P mutated
isoforms; TOM40 or empty backbone as control. Cells grown on
coverslips were fixed 48 h after infection with 4% paraformalde-
hyde for immunohistochemical analysis.
Mitochondria were labeled in vivo by incubation with 1 mM
MitoTracker (Life Technologies) in serum-free DMEM for
45 min. Detection of ROS production was performed in vivo
with CellROX Deep Red Reagent 5 mM (Life Technologies) for
45 minutes (co-incubation with MitoTracker). This reagent yields
a red cytoplasmic signal upon oxidation.
Quantification of Oxidative Damage to DNA by ELISA
DNA oxidative lesions were quantified by ELISA. In brief,
DNA was dissociated into single-strands by incubation at 95uC for
5 minutes and rapidly chilling on ice. DNA was digested to
nucleosides with nuclease P1 (15 U, Sigma) followed by treatment
with 8 units of alkaline phosphatase (Sigma) for 1 hr at 37uC. 8-
OHdG quantification was then performed with OxiSelectH
Oxidative DNA Damage ELISA Kit (Cell Biolabs, San Diego,
CA, USA) as per manufacturer’s instructions.
Lentivirus Construction for Delivery and Overexpression
of TOM40
Murine TOM4 cDNA (clone #3326417, OpenBiosystems) was
PCR amplified to include BamHI and ApaI restriction sites. This
was then cloned into the 3rd generation lentivirus vector to
generate the LV-TOM40 virus. The LV-control virus consists of
the same backbone containing the CMV promoter without
a transgene cloned downstream of promoter. Lentiviruses were
prepared as previously described by transient transfection in 293T
cells [26].
Stereotaxic Delivery of Lentiviruses to a-Syn Tg Mice
a-Syn tg mice and their non-transgenic litter mates (n = 8/
group, 10 months old) received stereotaxic injections of 3 ml of the
lentiviral preparations (2.56107 TDU) into the hippocampus and
cortex as previously described [27]. Mice were anesthesized and
received quadrilateral injections of either LV-TOM40 (n= 8, 4 a-
Syn tg, 4 non-tg), or LV-control (n = 8, 4 a-Syn tg, 4 non-tg) on
a Koft stereotaxic apparatus. Coordinates for the hippocampus:
AP 22.0 mm, lateral 1.5 mm, depth 1.3 mm; and for the cortex:
AP 20.5 mm, lateral 1.5 mm and depth 1.0 mm. Four weeks
after the lentiviral injection, mice were anesthetized with chloral
hydrate and flush-perfused transcardially with 0.9% saline. Brains
were removed and the right hemibrain was post-fixed in
phosphate-buffered 4% PFA (pH 7.4) at 4uC for 48 hours for
neuropathological analysis, while the left hemibrain was snap-
frozen and stored at 280uC for subsequent ATP and protein
analysis.
Stereological Analysis of TOM40, a-Syn, and 8-OHdG on
Brain Sections
Analysis of a-Syn accumulation was performed in serially-
sectioned, free-floating, blind-coded vibratome sections from tg
and non-tg mice treated with LV-TOM40 and control vectors.
Sections immunolabeled with antibodies against a-Syn and NeuN
(three from each mouse at 100 mm intervals) were analyzed by the
dissector method using the Stereo-Investigator System (MBF
Bioscience, Williston, VT) and the results were averaged and
expressed as numbers per mm3. Sections immunolabeled with
antibodies against TOM40 and GFAP were imaged with an
Olympus X digital microscope (BX51) and analyzed with the
ImageQuant program. Results are expressed as corrected optical
density. Sections immunolabeled with antibodies against 8-OHdG
were serially imaged with the laser scanning confocal microscope
(LSCM, MRC1024, BioRad) and analyzed with the Image 1.43
program (NIH), as previously described [28,29]. For each mouse,
a total of three sections were analyzed and results expressed as
pixel intensity. All sections were processed simultaneously, under
the same conditions.
All experiments were done blind coded and in triplicate. Values
in the figures are expressed as means 6 SEM.
Human Brain Samples
Human midbrain samples from five PD cases (75.3612.8 years)
and five age-matched non-neurodegenerative controls (69.1615.4
years) were provided by the German brain bank BrainNetH
following ethical approval by the Institutional Review Board
(ethics committee) of the University of Munich. Frozen brain
sections were cut with a cryostat and two 25 mm thick sections
were collected per brain. Protein extraction followed the same
protocol as described above for mouse brain sections.
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Statistical Analysis
Statistical analysis was performed with the SPSS 12.0 software
package (SPSS Inc., Chicago, IL, USA). The Kolmogorov-
Smirnov Test was used to check for normal distribution of the
data, in which case t-tests were applied to identify significant
(p,0.05) group differences. For multiple comparisons, the one-
way ANOVA with pos-hoc Fisher tests was used. All data proved
to be normally distributed.
Results
TOM40 Protein Levels are Altered in PD and a-Syn-
transgenic Mouse Brains
a-Synuclein is present at synaptic terminals and can be
identified at both the cytoplasmic and nuclear compartments. In
addition, a-Syn has been reported to localize to mitochondria, and
its translocation is presumably mediated by the mitochondrial
import machinery, after recognition of a mitochondrial targeting
sequence present in a-Syn [20]. The translocase of the outer
mitochondrial membrane (TOM) is a component of the import
machinery, and TOM40- the transmembranous domain of the
TOM complex- was reported to directly interact with a-Syn and
to be involved in its import into mitochondria [20,30]. We
hypothesized that a-Syn accumulation might induce alterations in
TOM40 that could might impair mitochondrial function. To
address this question we first investigated TOM40 protein levels in
postmortem midbrain samples from PD patients. Compared to
age-matched control subjects, PD brains showed a significant
decay in TOM40 levels (Figure 1A–D). In addition we evaluated
the levels of the mitochondrial import receptor TOM20, another
component of the TOM40 complex that participates in recogni-
tion of targeting sequences tethering the pre-sequence to the
complex and increasing import efficiency [31]. No alterations
where observed in TOM20 levels in PD brains, suggesting that the
observed alterations on TOM40 are specific rather than a conse-
quence of general decay of mitochondrial proteins (Figure 1A–D).
PD cases included in the present study were carefully selected
based on neuropathological examination postmortem, and we
further characterize them here by quantification of a-Syn levels.
All cases examined showed significant accumulation of a-Syn, with
3 (out of 5) showing increased aggregation of a-Syn (Figure 1 A).
Decay of TOM40 levels corresponded to a-Syn accumulation,
suggesting a functional link among these events. Moreover,
decreased levels of TOM40 protein were also observed in the
brains of the a-Syn transgenic mouse model of PD, when
compared to non-transgenic littermates, with no overt changes
on TOM20 levels (Figure 1 E–H), decays that also corresponded
with a-Syn-overexpression.
TOM40 is Altered in Wild-type and A53T- a-Syn
Accumulating Cells
The pathological hallmark of PD is the accumulation of a-Syn
in Lewy Body structures [9]. Two dominant mutations in a-Syn,
A53T and A30P cause familial early onset PD [13,32]. We
therefore investigated if the accumulation of wild type a-syn and
its most common mutated forms results in Tom40 decrease thus
impairing mitochondrial function. We generated an in vitro system
by infection of B103 rat neuroblastoma cells with lentiviral
constructs harboring human wild type a-Syn (LV-a-syn), muta-
tions A53T (LV-a-syn-A53T) or A30P (LV-a-syn-A30P), Tom40
(LV-Tom40) or a combination of these constructs. Overexpression
of wild-type a-syn and A53T mutant resulted in specific decay of
Figure 1. TOM40 protein levels are decreased in PD brains and in a-Syn transgenic mice. (A) Western blot analysis showing levels of
mitochondrial proteins TOM40 and TOM20 as well as of a-Syn on postmortem human brain samples from control subjects and PD patients (b-Actin
signal is shown as normalization control). (B) Densitometric analysis of TOM40 and TOM20 immunoreactivity. (C) Immunohistochemical detection of
TOM40 and TOM20 in control and PD brains. (D) Optical density analysis of TOM40 and TOM20 immunoreactivity. (E) Western blot analysis of Tom40,
Tom20 and human-a-Syn levels on whole brain homogenates from a-Syn-tg mice and non-transgenic littermate controls. (F) Densitometric analysis
of Tom40 and Tom20 on mice brains. (G) Immunohistochemical detection of Tom40 and Tom20 in a-Syn-tg and non-transgenic mice. (H) Optical
density analysis of Tom40 and Tom20 on mice brains. *p,0.05 per Student’s t test. Scale bar represents 25 mm.
doi:10.1371/journal.pone.0062277.g001
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Tom40, while Tom20 remained unaltered (Figure 2 A–B).
Interestingly, A30P mutation did not altered Tom40 levels. Both
mutations are located at the N-terminal fragment of a-Syn, in the
proximity of the encrypted mitochondrial signal. We speculate that
A30P mutation might alter the affinity of a-Syn for the
mitochondrial membranes, and therefore might not interact with
Tom40. We next overexpressed Tom40 on a-Syn-accumulating
cells by co-infection of B103 cells with LV-Tom40 (Figure 2 C–E).
Immunohistochemical detection of a-Syn on double-infected cells
showed increased Tom40 was able to reduce the accumulation of
a-Syn, both wild-type and A53T isoforms, while no effects were
observed on A30P (Figure 2 D–E). These results suggest a complex
regulatory feedback mechanism by which Tom40 and a-Syn
regulates the levels of each other. We hypothesize that, in the case
of Tom40 overexpression, restored mitochondrial function will
decrease oxidative stress preventing further misfolding of a-Syn
and might also contribute to redistribution and/or degradation of
protein aggregates.
Tom40 Alterations Induced by a-Syn Accumulation
Results in Increased Oxidative Damage and DNA
Deletions on the Mitochondrial Genome
We further evaluated if the observed reductions on Tom40
associated with accumulation of wild-type a-Syn and A53T might
increase oxidative stress. Overexpression of wild-type and A53T-
a-Syn, and to a lesser extent of A30P a-Syn, resulted in reduced
mitochondrial content as evidenced by Mitotracker labeling
(Figure 3 A–B), probably due to increased mitochondrial
autophagy in response to a-Syn accumulation as reported earlier
[33]. In addition, a-Syn overexpression increased ROS pro-
duction in the cytoplasm (Figure 3 C–D) and higher levels of
oxidative DNA lesions, evidenced by higher 8-OHdG (8-hydroxy-
29-deoxyguanosine) levels (Figure 3 E–F). Importantly, over-
expression of Tom40 on a-Syn-accumulating cells helped preserve
mitochondrial integrity, with concomitant reductions on ROS
production and oxidative DNA damage, in a support of
a functional relation between a-Syn, Tom40 and mitochondria
(Figure 3 A–F).
An important body of evidence from genetic analysis, post-
mortem human brain tissue examination and studies on animal
models strongly suggest that mitochondrial dysfunction is a key
pathological mechanism in PD, mainly leading to increased
oxidative stress [34]. After our observations showing increased
oxidative DNA lesions in a-Syn-accumulating cells, we analyzed 8-
OHdG levels in a-Syn transgenic mice brains. Immunohisto-
chemical analysis showed increased intensity of 8-OHdG staining
in cortical areas of a-Syn transgenic mice, when compared to non-
transgenic littermates. These results were supported by ELISA-
based quantification of 8-OHdG on brain homogenates (Figure 4
A and B).
In addition to generation of reactive oxygen species (ROS) and
oxidative stress, mitochondrial dysfunction results in damage and
deletions to mitochondrial DNA (mtDNA), which is particularly
susceptible to ROS generated by the respiratory chain due to its
physical proximity. We have previously shown large-scale mtDNA
deletions in postmortem human brain samples from patients
diagnosed with PD [6]. Therefore, we measured the levels of
mtDNA deletions in a-Syn transgenic mice. We detected large-
scale mtDNA deletions by long-extension PCR in brain homo-
genates from both transgenic animals and non-transgenic
littermates (Figure 4 C). Analysis of the resulting amplicons
showed a higher number of partial deletions in mtDNA on
Figure 2. Tom40 is reduced in B103 cells overexpressing wild type and A53T-a-Syn. B103 neuroblastoma rat cells were infected with
lentivirus encoding human a-Syn wild type (LV- a-Syn) or its mutated isoforms A53T (LV-a-Syn-A53T) and A30P (LV-a-Syn-A30P); Tom40 (LV-Tom40)
or a combination of these vectors. (A) Western blot detection of a-Syn, Tom40 and Tom20 on whole cell lysates from infected B103 cells. (B)
Densitometric analysis of Tom40 and Tom20 levels. (C) Efficient overexpression of Tom40 is achieved in B103 cells by infection with LV-Tom40. (D)
Immunohistochemical detection of a-Syn and Tom40 in B103 cells infected with the corresponding lentiviral constructs. (E) Pixel intensity analysis of
a-Syn levels, showing reduction of a-Syn in Tom40-overexpressing cells. *p,0.05 per Student’s t test. Scale bar represents 10 mm.
doi:10.1371/journal.pone.0062277.g002
a-Syn Dysregulation of TOM40 Alters Mitochondria
PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e62277
transgenic mice, i.e. higher number of shorter bands than intact
mitochondrial genome (approx. 10 Kb), which was better
conserved o non-transgenic littermates. In order to determine
the actual deletion load within the whole brain and within specific
neuronal populations, we applied real-time PCR analysis (qPCR).
Increased percentage of mtDNA deletions was confirmed on brain
homogenates from a-Syn transgenic mice in comparison to control
animals (Figure 4 D). We next analyzed if a-Syn accumulation
correlates with mtDNA damage at the single neuron level. Laser-
capture microdissection (LCM) of cortical neurons showing either
intense a-Syn staining (Figure 4 E, green labeling) or those testing
negative for a-Syn-immunoreactivity was followed by qPCR
determination of mtDNA deletions. Neurons accumulating a-
Syn contained a higher deletion load than neighboring neurons of
the same brain region without intense a-Syn immunostaining
(Figure 4 F). As a reference, the ratio between mitochondrial and
nuclear DNA copy number remained unchanged in both neuronal
populations sampled. These results strongly link a-Syn accumu-
lation to the induction of important deletions in mtDNA.
The human mitochondrial genome encodes a total of 37 genes,
including subunits of the complexes I, III, IV and V [35]. We
investigated the effects of a-Syn accumulation on the expression of
mitochondrial proteins. At the protein level, a-Syn transgenic mice
showed a significant decrease of the complex I subunit NDUFB8
(Figure 4 G–H), while subunits of the other 4 oxidative
phosphorylation (OXPHOS) complexes appeared unaltered.
These alterations in protein expression are expected to have
a profound impact on mitochondrial function.
Lentiviral-mediated Delivery of Tom40 Reverses a-
Synuclein-induced Mitochondrial Toxicity
Taken together, the above results suggest that impairment of
mitochondrial protein import is an early event that greatly
contributes to a-Syn toxicity. To test this hypothesis, we delivered
a lentiviral vector expressing Tom40 to the hippocampus of a-Syn
transgenic and control animals. Intracranial lentivirus injection
resulted in increased levels of Tom40 throughout the hippocampus
and dentate gyrus (Figure 5 A and B). Overexpression of Tom40
resulted in protection against oxidative DNA lesions induced by a-
Syn accumulation, as evidenced by reduced 8-OHdG levels in a-
Syn tg mice that approached those observed in non-transgenic
control animals (Figure 5 C and D). Four weeks after lentiviral
delivery of Tom40, ATP levels were increased in both, a-Syn tg
and control animals, suggesting a significant improvement of
mitochondrial function (Figure 5 E).
Overexpression of Tom40 Results in Redistribution of a-
Synuclein in Transgenic Mice Brains
Tom40 overexpression resulted in an increased of NeuN
postiitve cells in transgenic animals, which reached similar levels
to those observed in non-transgenic control mice (Figure 6 A and
C). In addition, a-Syn tg mice that received Tom40 lentiviral
injections showed reduced glial cell counts than the animals
injected with control virus (Figure 6 B and D). These results
suggest that Tom40 genetherapy was able to diminish neurode-
generative and inflammatory processes in brains of a-Syn tg mice.
As we previously observed in our in vitro cellular model, over-
expression of Tom40 appears to decrease a-Syn accumulation,
which now redistributes partly from cell bodies into the axons,
mirroring the physiological location of a-Syn into synaptic
terminals [36] (Figure 6 E and F), an effect that might be
associated to restored mitochondrial function.
Figure 3. Mitochondrial impairment and oxidative stress induced by a-Syn-accumulation is reduced by overexpression of Tom40.
B103 neuroblastoma rat cells were infected with lentivirus encoding human a-Syn wild type (LV- a-Syn) or its mutated isoforms A53T (LV-a-Syn-A53T)
and A30P (LV-a-Syn-A30P); Tom40 (LV-Tom40) or a combination of these vectors. (A) Immunohistochemical detection of mitochondria by in vivo
labeling with MitoTracker. (C) In vivo detection of mitochondria-derived reactive oxygen species (ROS) in cytoplasm by CellROX fluorogenic probes.
(E) Fluorescent immunolabeling of oxidative DNA lesions (anti-8-OHdG). (B, D and F) Pixel intensity analysis of the corresponding immunosignals.
Scale bar represents 10 mm. *p,0.05 per Student’s t test.
doi:10.1371/journal.pone.0062277.g003
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Figure 4. Alpha-synuclein overexpression results in oxidative DNA damage, alterations in respiratory chain complex I and
mitochondrial DNA deletions in transgenic mice brains. (A) Immuno-histochemical detection of 8-OHdG suggesting increased oxidative DNA
damage in a-Syn tg mice brains. (B) 8-OHdG levels were quantified on whole brain in a-Syn tg and non-transgenic control mice by ELISA. Scale bar
represents 25 mm. (C) Long extension PCR showing large-scale mtDNA deletions in a-Syn tg mice. (D) Quantitative determination of mtDNA deletions
by real-time PCR showing increased mtDNA deletion levels in the brain of a-Syn tg mice compared to control animals. (E) Immunostaining for a-Syn
(green signal) and NeuN (red signal; arrow marks the identical neuron in double labeling) used for Laser Capture Microdissection (LCM). Scale bar
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Discussion
Understanding the mechanisms of a-Syn-mediated neurotoxic-
ity and neurodegeneration is crucial for the development of
specific therapies for highly prevalent neurological diseases, such
as PD. Here we provide new evidence for a possibly under-
recognized pathomechanism by which extra-mitochondrial a-Syn
could interfere with mitochondrial function. We report here
a specific decrease in TOM40 protein levels both in mouse brain
homogenates as well as in human midbrain samples, inversely
associated with a-Syn accumulation. We show that, in addition to
wild type a-Syn, A53T-a-Syn also alters Tom40 levels, while
accumulation of A30P mutant has little effect on this system.
Reduction on Tom40 results in higher ROS production; increased
oxidative damage to the DNA accompanied by higher level of
mtDNA deletions; altered mitochondrial integrity and reduced
ATP production. Overexpression of Tom40 on a-Syn-accumu-
lating neuronal cells partially restores mitochondrial function,
reducing the oxidative burden and also impacting a-Syn
aggregation/accumulation. Although it is unclear how a-Syn
could promote the reduction in TOM40 levels, we found a highly
significant negative correlation between a-Syn and TOM40 by
performing data mining on expression levels derived from 381
human blood samples (data not shown) suggesting that a-Syn is
a negative regulator of TOM40 either directly or by indirect
mechanisms.
It is an open question by which mechanisms a-Syn promotes its
neurotoxicity and especially how it impacts mitochondria. Direct
interaction of a-Syn with intra-mitochondrial proteins, including
the OXPHOS complexes have been proposed [37]. It has been
recently shown that a-Syn is able to enter mitochondria via the
import channels by means of a mitochondrial targeting sequence
[20,37]. Additional work confirmed the intra-mitochondrial
localization of a-Syn, which, interestingly, was more abundant
in SN than in other brain regions in rat models [38]. Similar
findings were also reported in post mortem brain samples from PD
patients [20]. a-Syn interacts with TOM40, which is the channel-
forming b-barrel subcomplex and an essential part of the
mitochondrial import machinery [30,39]. Interestingly, mitochon-
drial localization of a-Syn is inhibited by antibodies directed
against TOM40 [20]. Inside mitochondria, a-Syn was shown to
interact with and to inhibit complex I, resulting in increased
oxidative stress [17,19,20,40], as we observed in the present study.
Mutations on a-Syn, in particular dominant mutations A53T
and A30P, have been associated with familial PD manifestations
[13,32]. These mutated isoforms of a-Syn are able to form
aggregates and to trigger neurotoxicity [19], and seem to increase
the shuttling of a-Syn between the nucleus and the cytoplasm [41].
We investigated the effects of wild type and mutated a-Syn on
Tom40 and present evidence here showing that wild type and
A53T mutations both specifically reduce Tom40 levels and alter
mitochondrial integrity and functioning, as evidenced by reduced
represents 250 mm in the upper panel and 25 mm in the close-up lower panel. (F) Quantification of mtDNA deletion levels by real-time PCR on
individual neurons with either intense or negative a-Syn immunoreactivity after LCM. (G) Western blot analysis of mitochondrial OXPHOS in brain
homogenates from a-Syn tg and wt mice. Lane 1 shows mitochondrial proteins standard marker. (H) Densitometric analysis of the levels of
Complexes I, II, III and IV. *p,0.05 per Student’s t test.
doi:10.1371/journal.pone.0062277.g004
Figure 5. Lentiviral delivery of Tom40 ameliorates a-Syn-induced mitochondrial alterations in transgenic mice. (A) Tom40
immunostaining in sagittal brain sections at the level of the hippocampus of non-transgenic (non-tg) controls and a-Syn-tg mice injected with control
lentivirus (LV-control) or with lentiviral delivery of Tom40. (B) Stereological analysis of Tom40 immunoreactivity (optical density) showing increased
signal after LV-Tom40 treatment. (C) Fluorescent immunolabeling of oxidative DNA lesions (anti-8-OHdG) in control and a-Syn tg mice treated with
LV-control or LV-Tom40. Scale bar represents 100 mm in the upper panel and 15 mm in the lower panel. (D) Stereological analysis of anti-8-OHdG
staining intensity reveals normal oxidative lesion load in tg animals overexpressing Tom40. (E) Quantification of ATP levels on brain homogenates
from mice treated with LV-control or LV-Tom40. *p,0.05 per Student’s t test.
doi:10.1371/journal.pone.0062277.g005
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mitochondrial content, increased ROS production, increased
DNA oxidative damage and reduced ATP production. The effects
of A30P mutant on mitochondria were subtle and its accumulation
did not alter Tom40 levels. While the precise molecular
mechanism that mediates the differential effects of a-Syn isoforms
on Tom40 and mitochondrial effects need to be further in-
vestigated, it has been reported that wild type and A30P
differentially interact with vesicles mimicking the outer mitochon-
drial membrane, and while both proteins have no affinity for it,
increased temperature of incubation increases the binding of the
wild-type, but not the A30P variant [42]. This lower affinity for the
outer membrane might alter the interaciton between Tom40 and
A30P.
Overactivation of autophagy has been suggested as a link
between intracellular accumulation of a-Syn and mitochondrial
dysfunction. In particular, activation of macroautophagy in
primary cortical neurons that overexpress mutant A53T a-Syn
leads to massive mitochondrial destruction and loss, associated
with bioenergetic deficit and neuronal degeneration [33]. Our
results showing reductions in mitochondrial content in wild type
and A53T a-Syn-accumulating cells are in line with this report,
and mitochondrial loss due to increased autophagy is a plausible
explanation.
Mice overexpressing mutant A53T a-Syn develop mitochon-
drial degeneration and apoptotic-like death of neocortical,
brainstem, and motor neurons [15]. We show here that over-
expression of wt a-Syn is also associated with mitochondrial
dysfunction. Extensive deletions on mtDNA should in principle
impact the expression of mitochondrial genome-encoded genes,
including subunits of complexes I-IV. We provide evidence
showing altered expression of complex I members, in line with
robust findings in human PD [4].
Dopaminergic neurons at the SN are the most severely affected
cell type in PD. Recent post mortem single cell analyses in brains
of sporadic PD patients and controls have shown that these
neurons contain high levels of clonally expanded somatic mtDNA
deletions [6,43]. This deletion load, higher than 50% of total
mtDNA in the neurons of PD patients is sufficient to cause
mitochondrial dysfunction [6]. We show that overexpression of
human wt a-Syn in mice is also associated with the accumulation
of such somatic and clonally expanded mtDNA deletions.
Furthermore, we provide evidence at the single neuron resolution,
supporting the notion that a-Syn accumulation correlates with
higher frequency of mtDNA deletions. Consistent with mtDNA
damage and complex I deficiency, a-Syn accumulation also lead to
decreased ATP production, indicative of mitochondrial impair-
ment.
Our data show a strong association between accumulation of a-
Syn, and impaired energy production, increased oxidative stress
and mtDNA damage and aberrant mitochondrial import. As
many of these factors can be either a cause or a consequence of the
others, it is difficult to establish a clear sequence of events. For
example, a-Syn is known to interfere with complex I itself, but, on
the other hand, complex I inhibition promotes the aggregation of
a-Syn [44]. It is plausible that many of these events feed a vicious
cycle that contributes to disease progression. We observed that
Figure 6. Tom40 overexpression reduces accumulation of a-Syn in neuronal cells. (A and B) Immunostaining of neuronal (anti-Neu N,
upper panel) and glial (anti-GFAP, lower panel) cells in non-transgenic control animals and a-Syn tg mice that received LV-control or LV-Tom40 gene
therapy. Scale bar represents 250 mm. (C and D) Stereological analysis of anti-NeuN and anti-GFAP-labeling, respectively (number of positive cells). (E)
Effect of Tom40 overexpression on a-Syn levels: immunostaining of a-Syn on sagittal brain sections from non-transgenic (non-tg) controls, a-Syn-tg
mice that received control lentivirus and a-Syn-tg mice injected with Tom40-lentivirus. Scale bar represents 250 mm in the upper panel and 50 mm in
the lower panel. (F) Stereological analysis of a-Syn immunosignal (number of positive cells) showing reduced a-Syn levels on Tom40-overexpressing
animals. *p,0.05 per Student’s t test.
doi:10.1371/journal.pone.0062277.g006
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wild type and A53T a-Syn accumulation triggered mitochondrial
dysfunction via decays in Tom40. These alterations are highly
relevant for the pathology of both, autosomal dominant and
sporadic PD manifestations.
A potential protective role of Tom40 preventing protein
misfolding and aggregation might not be exclusive for a-Syn.
Several genetic wide association studies have linked TOM40
polymorphisms with age of onset distribution in late-onset
Alzheimer’s disease (AD) manifestations (for a review see [45]).
TOM40 is in linkage disequilibrium with APOE e4 allele, an
established risk factor for AD [46]. Importantly, accumulation of
neurofilament light proteins (NFL) in the cerebrospinal fluid (CSF)
which marks neuronal damage, is higher in AD patients that carry
the APOE e4 allele, but only if they do not carry the short poly-T
variant of TOM40 associated with late onset AD, suggesting that
this mitochondrial protein may be protective against the dose
effect of APOE e4 [47].
Apo-E isoforms differentially regulate amyloid b (Ab) aggrega-
tion and clearance in the brain, and have distinct functions in
regulating brain lipid transport, glucose metabolism, neuronal
signaling, neuroinflammation, and mitochondrial function [48].
The protective function of TOM40 in AD might be related to Ab
aggregation and mitochondrial function integrity, in a similar
fashion as we report here for a-Syn in PD. In support of this
notion, TOM40 is significantly down-regulated in blood [49] and
frontal cortex of AD subjects compared to controls and is related
to abnormal mitochondrial dynamics in the brain [50]. Strikingly,
truncated amyloid precursor protein (APP) accumulates in the
protein import channels of mitochondria in AD brains, forming
stable complexes with TOM40 causing mitochondrial dysfunction.
Moreover, accumulation of APP in mitochondria varies with
severity of AD [51].
The protective effects of TOM40 might also extend beyond a-
Syn and Ab, as a recent study reported decreased levels of
TOM40 in the striatum and frontal cortex of Huntington’s disease
(HD) patients, associated with increased oxidative stress and
mutant Huntingtin oligomer accumulation in nuclei and mito-
chondria [52]. Although the functional relationship between
TOM40 decay and mitochondrial alterations remains to be
clarified for AD and HD, TOM40 appears as a novel pathological
theme common to ‘‘misfolding protein diseases’’ supporting our
hypothesis that decreased Tom40 leads to mitochondrial dysfunc-
tion and oxidative burden that feed a cycle of protein misfolding
and neuronal damage.
Our results show that lentivirus-mediated delivery of Tom40
was able to ameliorate the molecular phenotype observed in a-Syn
tg mice, as ATP production was restored and oxidative damage
was reduced in Tom40-treated animals, supporting a role for
Tom40 as a target for a-Syn-mediated mitochondrial dysfunction.
Importantly, we found that Tom40 genetherapy resulted in
reduced neurodegeneration and inflammation in the brains of a-
Syn tg mice, and effect that might contribute with decreased
accumulation of a-Syn in neuronal cells as we observed in that
treatment group. We hypothesized that higher levels of Tom40
results in improved mitochondrial function, reducing oxidative
loads and possibly facilitating a-Syn degradation by authogaphy or
preventing its misfolding [53,54].
In sum, we provide evidence showing that the interaction of a-
Syn with the mitochondrial protein import machinery, in
particular Tom40, might be an upstream event in a-Syn-induced
neurotoxicity and that targeting of this protein might represent
a novel therapeutic strategy in PD.
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